Stock Track | Moderna Plummets 5.05% as RBC Slashes Price Target to $32

Stock Track

Apr 03, 2025

Moderna, Inc. (MRNA) shares plunged 5.05% in pre-market trading on Thursday, following a significant price target cut by RBC Capital Markets. The investment bank lowered its target for Moderna from $40 to $32, while maintaining a Sector Perform rating on the stock.

The dramatic reduction in price target reflects growing concerns about Moderna's near-term prospects. This move by RBC aligns with the overall cautious sentiment among analysts, as FactSet reports that Moderna currently has an average rating of "hold" with a mean price target of $50.35.

The biotech company, known for its mRNA technology and COVID-19 vaccine, has been facing challenges as demand for coronavirus vaccines wanes. Investors are closely watching Moderna's pipeline and its ability to leverage its technology platform for other therapeutic areas. The sharp stock decline suggests that the market is adjusting its expectations for Moderna's future performance in light of the lowered price target.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1179607150"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179607150\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179607150?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-03 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179607150","market":"us","top_or_hot":-1,"title":"Stock Track | Moderna Plummets 5.05% as RBC Slashes Price Target to $32","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) shares plunged 5.05% in pre-market trading on Thursday, following a significant price target cut by RBC Capital Markets. The investment bank lowered its target for Moderna from $40 to $32, while maintaining a Sector Perform rating on the stock.</p>\n\n<p>The dramatic reduction in price target reflects growing concerns about Moderna's near-term prospects. This move by RBC aligns with the overall cautious sentiment among analysts, as FactSet reports that Moderna currently has an average rating of \"hold\" with a mean price target of $50.35.</p>\n\n<p>The biotech company, known for its mRNA technology and COVID-19 vaccine, has been facing challenges as demand for coronavirus vaccines wanes. Investors are closely watching Moderna's pipeline and its ability to leverage its technology platform for other therapeutic areas. The sharp stock decline suggests that the market is adjusting its expectations for Moderna's future performance in light of the lowered price target.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Plummets 5.05% as RBC Slashes Price Target to $32</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Plummets 5.05% as RBC Slashes Price Target to $32\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-04-03 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) shares plunged 5.05% in pre-market trading on Thursday, following a significant price target cut by RBC Capital Markets. The investment bank lowered its target for Moderna from $40 to $32, while maintaining a Sector Perform rating on the stock.</p>\n\n<p>The dramatic reduction in price target reflects growing concerns about Moderna's near-term prospects. This move by RBC aligns with the overall cautious sentiment among analysts, as FactSet reports that Moderna currently has an average rating of \"hold\" with a mean price target of $50.35.</p>\n\n<p>The biotech company, known for its mRNA technology and COVID-19 vaccine, has been facing challenges as demand for coronavirus vaccines wanes. Investors are closely watching Moderna's pipeline and its ability to leverage its technology platform for other therapeutic areas. The sharp stock decline suggests that the market is adjusting its expectations for Moderna's future performance in light of the lowered price target.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1179607150","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179607150","pubTimestamp":1743687189,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc.  shares plunged 5.05% in pre-market trading on Thursday, following a significant price target cut by RBC Capital Markets. The investment bank lowered its target for Moderna from $40 to $32, while maintaining a Sector Perform rating on the stock.The dramatic reduction in price target reflects growing concerns about Moderna's near-term prospects. This move by RBC aligns with the overall cautious sentiment among analysts, as FactSet reports that Moderna currently has an average rating","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"加拿大皇家银行(RBC)将目标价下调至32美元，Moderna股价暴跌5.05%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) shares plunged 5.05% in pre-market trading on Thursday, following a significant price target cut by RBC Capital Markets. The investment bank lowered its target for Moderna from $40 to $32, while maintaining a Sector Perform rating on the stock.\nThe dramatic reduction in price target reflects growing concerns about Moderna's near-term prospects. This move by RBC aligns with the overall cautious sentiment among analysts, as FactSet reports that Moderna currently has an average rating of \"hold\" with a mean price target of $50.35.\nThe biotech company, known for its mRNA technology and COVID-19 vaccine, has been facing challenges as demand for coronavirus vaccines wanes. Investors are closely watching Moderna's pipeline and its ability to leverage its technology platform for other therapeutic areas. The sharp stock decline suggests that the market is adjusting its expectations for Moderna's future performance in light of the lowered price target.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}